Cholestasis, progressive familial intrahepatic 1 clinical trials

The registry lists 33 studies for Cholestasis, progressive familial intrahepatic 1 across more than 10 countries. 13 are recruiting or about to start. 24 of them are mainly about Cholestasis, progressive familial intrahepatic 1 (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-13.

Get an email when these change. Save the Cholestasis, progressive familial intrahepatic 1 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Recruiting: 12
Completed: 11
No longer available: 4
Terminated: 1
Suspended: 1
Status unknown: 1

Phase

Phase 3: 5
Phase 2: 2
Phase 1: 2
Phase 4: 1

Where

United States: 10
France: 8
Italy: 7
Canada: 6
Belgium: 6
United Kingdom: 6

Who runs them

Mirum Pharmaceuticals, Inc. (8) · Ipsen (4) · Albireo (3) · Takeda (2) · IRCCS Azienda Ospedaliero-Universitaria di Bologna (2) · University Medical Center Groningen (2) · University of Pittsburgh (2) · Centre Hospitalier Universitaire de Liege (1)

Who develops what

Every programme with a company-led study here in the last two years, whatever its size: 1 programme from 1 company, 1 with this as their studies’ main aim; 0 with a live phase 3 study; 0 primary completions in the next 12 months.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

None given by two companies or more yet.

Programmes

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 1 programme — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (0)

Live phase 2 and 3 studies of these programmes. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

None in the next 12 months.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. Phase 4 trial recorded: a phase 4 study exists somewhere; approval here is not checked. Not read yet: approvals and labels, exclusivity, licences, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Cholestasis, progressive familial intrahepatic 1 studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Maralixibat	1	4	7
Odevixibat	0	1	2
Cholestyramine Resin	0	0	1

Coming up

0phase 3 studies under way

3studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 3

Nov 2026Odevixibat Outcomes in Patients With PFIC Versus an External Control Cohort (OvEC-PFIC) · Ipsen
Oct 2027Familial Intrahepatic Cholestasis-related Genes Associated with Disease Susceptibility in Hepato-biliary Cancers · IRCCS Azienda Ospedaliero-Universitaria di Bologna
Oct 2027Dental Dyschromia and Quality of Life in Early Prolonged Hyperbilirubinemia · University Hospital, Toulouse

Who these studies take

Of the 12 Cholestasis, progressive familial intrahepatic 1 studies recruiting now, 8 (67%) set no upper age limit and 4 (33%) stop at 75 or younger. 10 (83%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 1 (8%) take healthy volunteers.

Recruiting studies that take each age, of 12
Age	Women	Men
10	9 (75%)	9 (75%)
18	12 (100%)	12 (100%)
30	9 (75%)	9 (75%)
40	9 (75%)	9 (75%)
50	9 (75%)	9 (75%)
65	9 (75%)	9 (75%)
75	8 (67%)	8 (67%)
85	8 (67%)	8 (67%)

Across all 33 studies, recruiting or not: 52% stop at 75 or younger and 52% at 65; 82% take children; 0% are for women only and 3% for men only; 15% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

Studies

Recruiting first, then most recently updated. Showing 33 of 33. search them.